ARTHROPLASTY
Evicel fibrin sealant does not appear to reduce total blood loss/transfusion rates for TKA
J Arthroplasty. 2014 Aug;29(8):1516-2062 patients scheduled to undergo primary TKA for knee osteoarthritis were randomly allocated to receive a topical application of a novel fibrin sealant (Evicel) or standard treatment (no application of Evicel), with the purpose of examining its ability to limit blood loss and reduce the need for blood transfusions. Results of this trial revealed Evicel does not reduce total blood loss or transfusion rate compared to standard treatment.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
